INTRODUCTION
Psoriasis is a common papulo-squamous skin disease that affects approximately 2% of the UK population 1 • Clinical manifestations are varied, ranging from chronic erythematous, scaling, plaques situated over scalp, sacrum and extensor surfaces of knees and elbows to acute, small guttate lesions, erythroderma, nail involvement and psoriatic arthritis. Any age group may be affected although onset is usually between 20 and 30 years and sex incidence is equal. Genetic predisposition appears an important facilitator of disease expression and approximately one-third of affected patients have at least one first degree relative with the disease.
Light microscopic histological assessment of a plaque of psoriasis reveals two salient features: (i) epidermal hyperplasia; and (ii) an inflammatory infiltrate. The epidermal changesconsist of hyperplasia, an absent granular cell layer, microabscessesand incomplete keratinocyte differentiation, all of which contribute to formation of elevated scaling plaqucs/. The dermal and intradermal inflammatory infiltrate is comprised mainly of T cells 3 . Psoriasis is still characterized as being of unknown aetiology but current opinion favours the disease being immunologically-mediated and possibly autoimmune in nature. Evidence for such a hypothesis accrues from detailed laboratory and clinical research and the use of immunosuppressive agents, such as cyclosporin, as investigatory tools. Overall evidence hinges on several interacting components including: T cells; cytokine profiles; antigen-presentation; superantigens; epidermal stem cells, and major histocompatibility complex (MHC) associations.
THE IMMUNE BASIS
T cells appear central to the immune-mediation hypothesis and the epidermal and dermal inflammatory cell infiltrate in psoriasis is comprised predominantly of T cells. Valdimarsson and colleagues" studied the immunology of evolving cutaneous lesions of acute guttate psoriasis and observed that an intraepidermal influx of activated, HLA-DR +, CD4 + T cells was one of the earliest events. In comparison Correspondence to: J J Voorhees resolving plaques of psoriasis exhibit a relative reduction in activated CD4 + T cells within the epidermis". Undoubtedly CD4 + T cells are an important component of the dermal infiltrate but there are controversial issues regarding the predominant phenotype of the intraepidermal T cells observed in psoriasis. Other research groups have implicated CDS+ T cells as predominant in psoriatic epidermis' and find that reduction in this subset during treatment of psoriasis correlates most closely with disease resolution. There is little doubt that T cells, whatever their phenotype, within plaques of psoriasis are activated'[ in that they are HLA-DR +, express the interleukin (IL)-2 receptor (CD25)6 and secrete cytokines recognised as synonymous with lymphocyte activation-Leo IL-2 and interferon-y", It seems that activation and subsequent proliferation of T cells could be occurring in situ within plaques of psoriasis as 37% of CD45RO+ (memory) T cells in the dermis of such plaques are actively proliferating, as well as 25% of dermal dendritic antigen-presenting cells". This observation implies that activation signal(s) for T-cell proliferation probably reside within the skin. Considerable interest has centred around the cytokine profile within psoriatic plaques-particularly in regard to the observation by Mossman? that such cytokine profiles can be compartmentalized and designated as either Th 1 or Th 2 • A Th, cytokine profile is characterized by predominanceofIL-2, IL-12 and interferon-y9,lo whereas IL-4, IL-5 and IL-lO prevail in a Th 2 cytokine profile 9,lO-in essence a mutually exclusive Yin-Yang scenario. Cutaneous diseases in which Th] cytokines predominate include mycosis fungoides l l and tuberculoid leprosy!", Th 2 cytokineassociated diseases include atopic dermatitisl/ and lepromatous leprosy!", Plaques of psoriasis chiefly contain IL-2 and interferon-y, thus indicating a Th, profile disease. 13 ,14 The exclusivity of Th 1/Th 2 profiles is exemplified by the rarity of concurrence of psoriasis and atopic dermatitis, both common diseases, in the same individual. I5
Superantigens
The precipitating activation signal within psoriatic plaques is unknown, but candidates for such a signal are superantigens, other infectious agents or perhaps normally cryptic epitopes within skin that are revealed only after exposure to such antigens I 6. It has been known for many years that acute guttate psoriasis is often preceded by a streptococcal pharyngitis17. More than SO subtypes of streptococcus exist dependent on amino acid variability in the distal portion of the N-terminus component of the bacterial M proteinl'', However, and in distinction to rheumatic fever, there seem to be no specific subtypes of p-haemolytic streptococcus associated with psoriasis. T-cell lines isolated from psoriatic plaques and grown out in vitro proliferate in response to the M protein component of streptococcus16, a constituent that allows streptococcus to function as a superantigen. Superantigens have capacity to be presented to T cells by antigenpresenting cells without recourse either to intracellular processing or presentation within the peptide-binding groove of the antigen-presenting cell!". Sequence homology between streptococcal M6 protein and a 50 kDa type I keratin/", keratin 14, implies that clonal T-cell proliferation directed against streptococcus may cross-react with an unmasked keratin epitope. Indeed, Swerlick et ai. 21 have demonstrated cross-reactivity between epidermal keratins and streptococci. Superantigens, including streptococcus, are presented by antigen-presenting cells to distinct VfJ regions of the T-cell receptor and this process eventuates in local clonal expansion of T cells expressing the relevant VfJ region. VfJ-expressing T-cell clones appear to be preferentially over-expressed in skin lesions of acute 22 and guttate 23 psoriasis as compared to peripheral blood of the same patients, and are mainly expressed by CDS+ T cells/". Such evidence of VfJ-expressing T cells in plaques lends support to the concept of a superantigen-driven event in psoriasis. However, recent work 25 utilizing polymerase chain reaction technology has identified neither clonality nor over-expansion of Vp-expressing T cells in chronic lesions of plaque psoriasis. Maybe superantigens, if important in this context, are only responsible for initiation of psoriatic lesions but not for their maintenance, which could be mediated by a self-antigen.
Genetics
Family studies and clinical experience dictate that psoriasis is a genetic disease-most likely polygenic or autosomal dominant with incomplete penetrance. Monozygotic and dizygotic twins exhibit approximately 70% and 20% concordance, respectively, for psoriasis 26 ,27. The less than 100% concordance for psoriasis observed in monozygotes implies the necessity of environmental factors for full clinical expression of disease. Such environmental factors may be Phaemolytic streptococci or other infectious agents. Despite intensive efforts to identify a candidate gene or genes for psoriasis, only one locus has been identified so far, situated on chromosome 17q, in an American kindred/". Research groups elsewhere in the USA and in Europe have been unable to identify a similar genetic locus in kind reds under their stud y 29 . It is therefore possible that different kindreds have different genetic loci for psoriasis. Early onset, so called type 130, psoriasis occurring for the first time in individuals under 40 years of age is usually associated with a strong family history of psoriasis and MHC Class I-HLA-Cw6 (85%). Later onset, type II30, sporadic psoriasis peaking at around 60 years of age has no such associations. HLA-Cw6 in common with HLA-Cw4 and HLA-Cw7 is characterized by an alanine for threonine substitution at position 73 of the antigen-binding cleft of HLA-C31. In studies in Japanese patients with psoriasis 32 the familial association is not with HLA-Cw6 but with HLA-Cw7. These observations imply that the C-pocket of the antigen-binding groove of HLA-C is important for presentation of the putative psoriasis antigen. The concurrence of HLA-DQ9 and HLA-Cw6 is highly predictive of psoriasis susceptibilit y33, although HLA-DQ9 by itself does not predispose to psoriasis. It is unusual for an autoimmune disease to be strongly linked to MHC class I although this may indicate that MHC class I-associated CD8+ T-lymphocytes are of integral importance to maintenance of psoriasis lesions.
T cells and stem cells
T-cell activation requires at least two signals34: (i) an antigenspecific signal in conjunction with MHC class lIII; and (ii) a second costimulatory signal provided by antigen-presenting cells (i.e. Langerhans' cells or dendritic cells in the case of skin). Both these types of antigen-presenting cells express the costimulatory molecules 87-1 and B7-2 35-which are ligands or receptors for CD28 on T cells. Costimulation is a requisite catalyst for full T-Iymphocyte activation and concomitant IL-2 production. A subtype of B7, B7-3, is expressed on keratinocytes, cells which themselves are capable of antigen-presentation 36. At present it is unclear whether CD28/B7-3 interactions are sufficient to provide T-cell costimulation although keratino-cy1:es may rely on other as yet ill-defined costimulatory pathways-". The presence of CD28+ T-cells within plaques of psoriasis raises the possibility that self costimulation may occur within a developing psoriatic lesion-", Furthermore, it appears that bystander T cells can be activated in an antigenindependent manner by certain combinations of cytokines or by UM4D4 38 , thereby abrogating the need for an initiating antigenic signal for all T cells.
Unlike researchers investigating other autoimmune diseases such as multiple sclerosis and rheumatoid arthritis, those of us involved in psoriasis research are at a disadvantage in that there is no animal model for psoriasis and there is considerable uncertainty as to the identity of antigen(s) perpetuating the inflammatory response. Thus newer therapeutic modalities for psoriasis can only be tested in vitro (an unsatisfactory arrangement) or directly in man. We can, however, take profit by immunopharmacological advances in other autoimmune diseases, such as multiple sclerosis, diabetes mellitus and rheumatoid arthritis, that benefit from the availability of animal models. Autoimmunity results from aberrant self-recognition, i.e. inappropriate immunological responses directed against self-antigens that have not engendered tolerance. Putative antigens in psoriasis could be keratin or a component of keratin although this is by no means as clear cut as the antigenicity of myelin basic protein in mulitple sclerosis 39 or collagen II in rheumatoid arthritist", How do T cells, whether they be activated by antigens or otherwise, stimulate epidermal keratinocyte hvperproliferation, as observed in psoriasis? Within normal human epidermis there are at least two populations of potentially proliferative keratinocyte subsets, both of which express {31 integrin (CD29)41. The basal keratinocyte stem cell population (slowly cycling, small cells) are identified as CD29+ Kl /K10-and are undifferentiated; the other subset of cells are designated CD29+ KI/K10+, and as such are higWy proliferative, suprabasal and committed to differentiation, so called transit amplifying cells 41. In psoriasis, it appears that the CD29+ K 1/KlO-, stem cell population has shifted from phase Go in the cell cycle to an actively proliferating mode'": Cytokines and/or growth-factors from T cells isolated from psoriasis plaques are able to stimulate proliferation ofCD29+ K 1/K10-stem cells of uninvolved skin from patients with psoriasis but are unable to stimulate proliferation of stem cells taken from normal skin 42. Strange et al. 4 3 have studied the growth-promoting properties of T cells cloned from psoriatic lesions and observe that no single cytokine produced by such T cells, including intcrferon-j, transforming growth factor-{3 (TGF-{3), IL-2, IL-3, IL-6, IL-8 and GM-CSF, is directly responsible for T-cell stimulation of keratinocyte growth. However, granulocyte macrophage colony stimulating factor (GM-CSF) and interferon-y prevail in supernatants from cultured T cells isolated from psoriatic plaques, and it appears that the presence of interferon-y is crucial in cooperation with other factors (cytokines and growth factors) for psoriatic stem cells to enter the proliferative cell cycle 43.
Adhesion molecules
Further evidence that lymphocytes are being actively recruited into the skin comes from research on endothelial cells. Probably the very earliest events to occur in a psoriatic lesion are those related to vascular endothelium. For leucocytes to gain access to the dermis they must first bind to endothelial cells lining dermal capillary walls-achieved by binding to adhesion molecules induced and/ or upregulated on endothelial cells44-46. Initially, lymphocytes are marginated to the edge of vascular flow as a result of vasodilatation followed by initial upregulation of adhesion receptors P-se!ectin, E-se!ectin and ultimately intercellular adhesion molecule-I (ICAM-I), and vascular cell adhesion molecule-I. These processes facilitate initial adherence of a unique population of circulating skin-homing T cells (recognized by the antibody HECA-452) to capillary'? walls and their subsequent diapedesis into the dermis and epidermis. Additionally ICAM-I is focally and strongly induced probably by interferon-y and tumour necrosis factor-IX on epidermal keratinocytes within psoriatic plaques'", Lymphocyte function-associated antigen-l (LFA-I), the ligand for ICAM-l, is expressed by T cells and thus intraepidermal T cells are able to bind keratinocvtes'tt and the resultant close apposition permits paracrine interactions between the two cell types and subsequent keratinocyte proliferation.
Immunopharmacology
Although treatments for psoriasis were originally aimed at inhibiting the rapidly proliferating keratinocytes of the epidermal compartment, nowadays dermatologists and pharmacologists are developing and utilizing therapies that are more 'upstream' in the psoriatic process and specifically target T-cell function and activity. Most notably cyclosporin, a relatively specific immunosuppressive, has been in the vanguard of this immunopharmacological approach to psoriasis treatment 48,49. Cyclosporin and a structurally dissimilar compound, FK506 5o, are highly effective treatments for psoriasis. Both cyclosporin and FK506 act as prodrugs by binding to cytoplasmic immunophilin receptors, the consequent receptor / prodrug complex inhibiting calcineurin phosphatase-an enzyme integral to cellular signal transduction. Calcineurin phosphatase dephosphorylates cytoplasmic nuclear factor of activated T cells (NFAT) thereby facilitating its passage to the nucleus and subsequent IL-2 production. 51 In essence cyclosporin and FK506 target T cells and inhibit both their proliferation and cytokine production. There is little, if any, evidence that either cyclosporin or FK506 directly inhibit keratinocyte proliferation. Analysis of skin biopsies taken from psoriasis plaques of patients during their first week of cyclosporin treatment, and prior to any clinical improvement, revealed significant reductions in mRNA for IL-I {3 and IL-8 52. This observation is circumstantial evidence that cyclosporin is inhibiting T-cell function and subsequent cytokine drive to keratinocyte proliferation. Intravenous administration of anti-CD4 monoclonal antibodies produces short-term improvement or clearance of psoriasis 53,54, further evidence for the integral role of T cells in this disease. The CD4 antigen is not unique to T cells but the high-affinity IL-2 receptor is, and if therapies targeting this receptor were efficacious, this would constitute strong evidence that psoriasis is a T -cellmediated disease. A therapy of this specificity does exist, namely DAB 389IL-2, a fusion protein in which IL-2 replaces the receptor-binding domain of diphtheria toxin. This adulterated toxin is a selective destroyer of cells expressing high-affinity IL-2 receptors; such cells are activated T cells.
Gottlieb et aJ. 5 have recently demonstrated that intravenously administered DAB 389IL-2 produces clinical and histological improvement in some patients with psoriasis, and such improvement strongly correlates with a reduction in intraepidermal T cells. Corroborative evidence comes from the anecdotal observation that psoriasis clears following administration of T-cell specific anti-CD3 antibodies'<.
Future therapeutic strategies in psoriasis will most probably be of an immunopharmacological nature such as targeting of specific VfJ T-cell clones, endothelial adhesion molecules or maybe use of recombinant adhesion molecules such as soluble rCAM-t. Until the antigen in psoriasis is described, immunodulation of the psoriatic process could be achieved by vaccination to stretches of amino acids from the relevant VfJ chain of T cells isolated from an individual's psoriatic plaques. Other approaches could be along the lines of biological response modification-suppressing or normalizing the Th, profile of psoriasis. Thus, aclministration of IL-l 0 (a Th 2 cytokine) might reduce the inflammatory events seen in psoriasis. This biological response modification strategy has already been demonstrated to some effect in dermatology, in that atopic dermatitis, a Th 2 disease, responds to treatment with subcutaneous injections of interferon-y, a Th 1 cytokine-", Disparate molecules including retinoids, calcipotriol, calcitriol, corticosteroids and cyclosporin are efficacious treatments for psoriasis57. Glucocorticoids, retinoids and vitamin D all belong to the supergene family of nuclear hormone receptors58 which also includes progesterone, oestrogen and thyroid hormone. The hormone-receptor complex, in response to ligand binding, localises to the cell nucleus and binds to DNA sequences within the promoter regions of target genes referred to as hormone response elements". Such binding may result in induction or repression of that gene. In addition to directly regulating inflammatory cytokines-" glucocorticoids have indirect but important downreguiating effects on cytokine production. Such indirect effects involve a nuclear transcription factor, AP_160, important in IL-2 gene transcription. AP-l is a necessary partner for NFAT and in the presence of hormone the hormone receptor binds to the AP-l component of NFAT thereby impairing assembly of the NFAT! AP-l complex and hence its inability to induce the It-2 gene 59 . Thus interference of glucocorticoid!receptor complex with NFAT binding impairs lymphocyte activation. It is possible that retinoids and vitamin D may interfere with NFAT action in the same way as glucocorticoids, indeed vitamin D inhibits experimental allergic encephalomyelitis (a multiple sclerosis model). Cyclosporin and FK506 also abrogate the psoriatic process by inhibition of NFAT transfer to the T-cell nucleus. Thus, NFAT! AP-l appears to be a crucial target for heterogeneous antipsoriatic drugs and future pharmacological immune modulators will specifically target this important complex in T-cell activation.
CONCLUSIONS
The putative autoimmune status of psoriasis is a developing concept and one that needs further clarification. Most psoriasis pathogenesis watchers would agree that T cells are integral to the initiation and maintenance of epidermal keratinocyte proliferation observed in psoriasis. Disease initiation may be dependent on influx of activated CD4+ T cells and its maintenance dependent on CDS+ T cells, thereby providing the link to both MHC class I and class II associations. The exact combinations of cytokines or growth factors necessary for subsequent T -cell-driven keratinocyte proliferation are still uncertain but are consistent with a Th 1 profile in which interferon-y is a vital component. Most likely, psoriasis is an autoimmune disease, of as yet unknown precipitating antigens, set amidst a background of a critical permissive genetic constitution. If the antigen(s) and! or the gene(s) for psoriasis are identified then oral tolerance therapies and maybe gene therapy itself are entertainable strategies for the future.
